CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Beginning balance at Dec. 31, 2019		$ 15	$ 270,492	$ (340,829)	$ (70,322)
Beginning balance (in shares) at Dec. 31, 2019	[1]	14,838,213
Issuance of common stock and warrants, net of issuance cost		$ 18	41,325		41,343
Issuance of common stock and warrants, net of issuance cost (in shares)	[1]	17,604,423
Note receivable from issuance of common stock and warrants			(4,000)		(4,000)
Share-based compensation related to stock options			698		698
Net loss for the period				(2,483)	(2,483)
Ending balance at Jun. 30, 2020		$ 33	308,515	(343,312)	(34,764)
Ending balance (in shares) at Jun. 30, 2020	[1]	32,442,636
Beginning balance at Mar. 31, 2020		$ 33	308,248	(339,162)	(30,881)
Beginning balance (in shares) at Mar. 31, 2020	[1]	32,442,636
Share-based compensation related to stock options			267		267
Net loss for the period				(4,150)	(4,150)
Ending balance at Jun. 30, 2020		$ 33	308,515	(343,312)	(34,764)
Ending balance (in shares) at Jun. 30, 2020	[1]	32,442,636
Beginning balance at Dec. 31, 2020		$ 35	320,280	(347,352)	(27,037)
Beginning balance (in shares) at Dec. 31, 2020	[1]	34,765,280
Issuance of common stock, net of issuance cost		$ 9	37,616		37,625
Issuance of common stock, net of issuance cost (in shares)	[1]	8,749,999
Issuance of common stock under the Sales Agreement, net		$ 2	8,573		8,575
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	1,867,552
Share-based compensation related to stock options			832		832
Share-based compensation related to restricted stock awards			562		562
Exercise of warrants (in shares)	[1]	173,816
Net loss for the period				(16,716)	(16,716)
Ending balance at Jun. 30, 2021		$ 46	367,863	(364,068)	3,841
Ending balance (in shares) at Jun. 30, 2021	[1]	45,556,647
Beginning balance at Mar. 31, 2021		$ 46	367,285	(352,827)	14,504
Beginning balance (in shares) at Mar. 31, 2021	[1]	45,382,831
Share-based compensation related to stock options			322		322
Share-based compensation related to restricted stock awards			256		256
Exercise of warrants (in shares)	[1]	173,816
Net loss for the period				(11,241)	(11,241)
Ending balance at Jun. 30, 2021		$ 46	$ 367,863	$ (364,068)	$ 3,841
Ending balance (in shares) at Jun. 30, 2021	[1]	45,556,647

[1] Common stock, $0.001 par value; Authorized – as of June 30, 2021 and 2020 - 120,000,000 shares.